AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

โ† Trials
๐Ÿงช

40 Hz Light Neurostimulation for Patients With Depression (FELIX)

RecruitingNAAges 18 Years - 75 YearsAllKlaus Martiny
๐Ÿ’ฌ

In plain words

What the trial is, and whether it could suit you

Recent research in mice models of Alzheimer's disease (AD) has demonstrated that one hour per day of exposure to 40 Hz flickering light therapy can halt the disease's progression, and improve cognition and memory. Moreover, recent data suggest that 40 Hz light stimulation may induce neuroplasticity and reduce neuroinflammation. In this study, the investigators aim to evaluate the antidepressant effects of 40 Hz light stimulation in Major Depressive Disorder (MDD). Patients will be exposed to 40 Hz invisible spectral flickering light (active setting) or continuous non-flickering white light (sham setting) in a home setting for 1 hour each day.

Sign in to get the eligibility rules as simple questions to take to your doctor.

๐Ÿ“‹ Eligibility rules (as published)
Inclusion Criteria: 1. Subjects between 18 and 75 years of age. 2. Subjects with a diagnosis of major depressive episode and currently experiencing a depressive episode according to DSM-5 3. Subjects with an MDI score \> 21 at screening 4. Subjects on stable medication and/or psychotherapy for at least 4 weeks before starting the trial. 5. Subjects, who are willing to comply with the scheduled plan and are able to use the device for 1 hour per day for 6 weeks. 6. Subjects who can understand the oral and written study information and willing to sign an informed consent. Exclusion Criteria: 1. Subjects with a history of photosensitive migraines and/or epileptic seizures 2. Subjects with a known eye disorder that might be sensitive to light treatment. 3. Subjects with a known history of bipolar disorder according to DSM-5 criteria 4. Subjects with suicidal ideation corresponding to a score of 2 or more on the HAM-D 17 scale item 3 or if the patient or investigator is uncertain of the degree of suicidal risk 5. Subjects with current psychotic symptoms. However, subjects with a prior psychotic depression or subjects with an actual psychotic depression episode that at the time of informed consent no longer fulfills the psychosis criteria are allowed to participate. 6. Subjects with current drug or alcohol dependence based on their medical records or the M.I.N.I. interview. 7. Subjects with a known history of borderline personality disorder 8. Subjects currently enrolled in another investigational treatment study. 9. Subjects with progressive neurodegenerative or neoplastic disease. 10. Subjects who are unable to understand the study procedures or handling of the NSS device. 11. Subjects who are pregnant at the time of inclusion or unsafe contraception in women of fertile age
๐Ÿ’Š

What it tests

  • Neurostimulation System (NSS): Active Setting
  • Neurostimulation System (NSS): Sham Setting
๐Ÿ“

Where

1 site
Mental Health Centre Copenhagen
Copenhagen, Denmark
๐Ÿค Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible โ€” always decide together with your own doctor.
๐Ÿ›ก๏ธ

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it โ€” not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use ยท Privacy